文献速递肿瘤 PET/CT

肿瘤突变负荷与2-[18F]FDG PET SUVmax的相关性研究

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients.
PubMed 文献 · EJNMMI Res · 2020-12-09

本研究纳入1923例多癌种患者,筛选出273例符合条件者(影像/活检前未接受系统治疗,且PET/CT与组织活检间隔6个月内),分析肿瘤突变负荷(TMB)与SUVmax的关系。结果显示TMB与SUVmax呈线性相关(p < 0.001),多因素分析中仅TMB与SUVmax独立相关,年龄、性别和肿瘤器官均无独立相关性。

要点

  • TMB与SUVmax呈线性相关(p < 0.001)
  • 多因素分析仅TMB独立相关,年龄性别器官无影响
  • SUVmax或可无创替代TMB预测免疫治疗反应

核心结论

  • TMB与2-[18F]FDG PET/CT的SUVmax呈线性相关,多因素分析中仅TMB与SUVmax独立相关。

研究设计与样本

  • 本回顾性 pilot 研究分析了1923例具有TMB值的多癌种患者,其中273例符合纳入标准:影像/活检前未接受系统治疗,且PET/CT在组织活检前6个月内完成。

主要发现

  • TMB与SUVmax之间存在线性相关(p < 0.001)。
  • 多因素分析中,仅TMB与SUVmax独立相关,年龄、性别和肿瘤器官均无独立相关性。

临床怎么用

  • SUVmax作为常规无创PET/CT参数,可能与需组织活检的TMB相关,但能否用于免疫治疗反应分层尚需进一步研究。

局限性

  • 本研究为 pilot 研究,样本量有限(273例符合条件),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography-computed tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. METHODS: In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. RESULTS: We found a linear correlation between TMB and SUVmax (p < 0.001). In the multivariate analysis, only TMB independently correlated with SUVmax, whereas age, gender, and tumor organ did not. CONCLUSION: Our observations link SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Haghighat Jahromi A, Barkauskas DA, Zabel M, et al. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res. 2020. PMID: 33296034. doi:10.1186/s13550-020-00732-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。